CN1137891C - 生长激素促分泌素的制备方法 - Google Patents

生长激素促分泌素的制备方法 Download PDF

Info

Publication number
CN1137891C
CN1137891C CNB001053884A CN00105388A CN1137891C CN 1137891 C CN1137891 C CN 1137891C CN B001053884 A CNB001053884 A CN B001053884A CN 00105388 A CN00105388 A CN 00105388A CN 1137891 C CN1137891 C CN 1137891C
Authority
CN
China
Prior art keywords
compound
general formula
methyl
oxo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB001053884A
Other languages
English (en)
Chinese (zh)
Other versions
CN1270960A (zh
Inventor
F��R����ʲ
F·R·布什
C·K－F·奇
÷
C·N·梅尔茨
R·J·波斯特
P·R·罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1270960A publication Critical patent/CN1270960A/zh
Application granted granted Critical
Publication of CN1137891C publication Critical patent/CN1137891C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CNB001053884A 1999-02-26 2000-02-25 生长激素促分泌素的制备方法 Expired - Lifetime CN1137891C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12274599P 1999-02-26 1999-02-26
US60/122,745 1999-02-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA031075525A Division CN1515570A (zh) 1999-02-26 2000-02-25 吡唑并[4,3-c]吡啶-3-酮L-酒石酸盐的制备方法

Publications (2)

Publication Number Publication Date
CN1270960A CN1270960A (zh) 2000-10-25
CN1137891C true CN1137891C (zh) 2004-02-11

Family

ID=22404505

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA200610073385XA Pending CN1837205A (zh) 1999-02-26 2000-02-25 吡唑并[4,3－c]吡啶－3－酮L－酒石酸盐的制备方法
CNA031075525A Pending CN1515570A (zh) 1999-02-26 2000-02-25 吡唑并[4,3-c]吡啶-3-酮L-酒石酸盐的制备方法
CNB001053884A Expired - Lifetime CN1137891C (zh) 1999-02-26 2000-02-25 生长激素促分泌素的制备方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNA200610073385XA Pending CN1837205A (zh) 1999-02-26 2000-02-25 吡唑并[4,3－c]吡啶－3－酮L－酒石酸盐的制备方法
CNA031075525A Pending CN1515570A (zh) 1999-02-26 2000-02-25 吡唑并[4,3-c]吡啶-3-酮L-酒石酸盐的制备方法

Country Status (43)

Country Link
US (2) US6541634B2 (enExample)
EP (2) EP1449842A1 (enExample)
JP (3) JP3437813B2 (enExample)
KR (2) KR100372063B1 (enExample)
CN (3) CN1837205A (enExample)
AP (1) AP1221A (enExample)
AR (2) AR029617A1 (enExample)
AT (1) ATE277944T1 (enExample)
AU (1) AU764122B2 (enExample)
BG (1) BG104175A (enExample)
BR (2) BRPI0000967B8 (enExample)
CA (1) CA2299495C (enExample)
CO (1) CO5160252A1 (enExample)
DE (1) DE60014212T2 (enExample)
DK (1) DK1031575T3 (enExample)
DZ (1) DZ3018A1 (enExample)
EA (1) EA003218B1 (enExample)
EE (1) EE200000193A (enExample)
ES (1) ES2226712T3 (enExample)
GT (1) GT200000018A (enExample)
HN (1) HN2000000021A (enExample)
HR (1) HRP20000103A2 (enExample)
HU (1) HUP0000907A3 (enExample)
ID (1) ID24861A (enExample)
IL (2) IL134599A (enExample)
IN (1) IN192352B (enExample)
IS (1) IS5380A (enExample)
MA (1) MA25072A1 (enExample)
NO (1) NO20000965L (enExample)
NZ (1) NZ503062A (enExample)
OA (1) OA11325A (enExample)
PA (1) PA8491201A1 (enExample)
PE (1) PE20001550A1 (enExample)
PL (1) PL338628A1 (enExample)
PT (1) PT1031575E (enExample)
SG (1) SG90096A1 (enExample)
SI (1) SI1031575T1 (enExample)
SK (1) SK284982B6 (enExample)
TN (1) TNSN00035A1 (enExample)
TR (1) TR200000536A2 (enExample)
TW (2) TWI286142B (enExample)
UA (1) UA70306C2 (enExample)
ZA (1) ZA200000888B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US9117477B2 (en) 2013-05-08 2015-08-25 HGST Netherlands B.V. Perpendicular magnetic recording media having novel seed layer
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
US5609150A (en) 1995-04-18 1997-03-11 Maged; Jeffrey M. Method for dilating respiratory passages
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ATE356139T1 (de) 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式
CN105164129B (zh) * 2013-05-28 2018-01-19 拉夸里亚创药株式会社 多晶型物形式

Also Published As

Publication number Publication date
EP1031575A1 (en) 2000-08-30
IL134599A (en) 2006-12-10
CO5160252A1 (es) 2002-05-30
EE200000193A (et) 2000-10-16
EP1031575B1 (en) 2004-09-29
DK1031575T3 (da) 2005-01-03
BRPI0000967A (pt) 2001-09-11
US20020002283A1 (en) 2002-01-03
KR20020065455A (ko) 2002-08-13
SI1031575T1 (en) 2005-02-28
TR200000536A2 (tr) 2000-09-21
KR100372063B1 (ko) 2003-02-14
HK1030219A1 (en) 2001-04-27
PT1031575E (pt) 2004-11-30
DZ3018A1 (fr) 2004-03-20
BG104175A (bg) 2000-12-29
BRPI0000967B1 (pt) 2012-06-12
NO20000965D0 (no) 2000-02-25
US6541634B2 (en) 2003-04-01
BRPI0017522A2 (enExample) 2009-12-22
KR20010006698A (ko) 2001-01-26
JP4051314B2 (ja) 2008-02-20
ZA200000888B (en) 2001-08-23
IL157103A (en) 2007-07-24
IL157103A0 (en) 2004-02-08
IL134599A0 (en) 2001-04-30
AR029617A1 (es) 2003-07-10
EA200000172A2 (ru) 2000-08-28
EA200000172A3 (ru) 2000-10-30
NO20000965L (no) 2000-08-28
CN1515570A (zh) 2004-07-28
AP1221A (en) 2003-11-03
EA003218B1 (ru) 2003-02-27
JP2003327585A (ja) 2003-11-19
PL338628A1 (en) 2000-08-28
TNSN00035A1 (fr) 2005-11-10
IN192352B (enExample) 2004-04-10
PA8491201A1 (es) 2001-04-30
TW200718702A (en) 2007-05-16
NZ503062A (en) 2001-07-27
BRPI0017522B8 (pt) 2021-05-25
AP2000001754A0 (en) 2000-03-31
ID24861A (id) 2000-08-31
CA2299495A1 (en) 2000-08-26
US20030158414A1 (en) 2003-08-21
AR053722A2 (es) 2007-05-16
DE60014212T2 (de) 2005-12-15
AU764122B2 (en) 2003-08-07
SG90096A1 (en) 2002-07-23
JP3437813B2 (ja) 2003-08-18
JP2000247974A (ja) 2000-09-12
JP2003261565A (ja) 2003-09-19
BRPI0017522B1 (pt) 2013-09-24
UA70306C2 (en) 2004-10-15
AU1947100A (en) 2000-08-31
SK2302000A3 (en) 2000-11-07
HUP0000907A2 (en) 2001-03-28
CN1837205A (zh) 2006-09-27
HRP20000103A2 (en) 2001-04-30
TWI286142B (en) 2007-09-01
CN1270960A (zh) 2000-10-25
MA25072A1 (fr) 2000-10-01
PE20001550A1 (es) 2001-01-11
SK284982B6 (sk) 2006-03-02
EP1449842A1 (en) 2004-08-25
US6673929B2 (en) 2004-01-06
CA2299495C (en) 2010-06-15
HU0000907D0 (en) 2000-04-28
OA11325A (en) 2003-10-27
ES2226712T3 (es) 2005-04-01
HUP0000907A3 (en) 2001-05-28
DE60014212D1 (de) 2004-11-04
BRPI0000967B8 (pt) 2021-12-07
IS5380A (is) 2000-08-27
HN2000000021A (es) 2001-02-02
GT200000018A (es) 2001-08-16
ATE277944T1 (de) 2004-10-15
KR100361783B1 (ko) 2002-11-22

Similar Documents

Publication Publication Date Title
CN1231478C (zh) 光学活性的哌啶中间体的制备方法和该中间体
CN1304390C (zh) 新颖的γ—分泌酶抑制剂
CN1057294C (zh) 3,4,4-三取代的哌啶基-n-烷基羧酸盐类化合物的制备及中间体
CN1088456C (zh) 取代的噁唑烷需钙蛋白酶和/或组织蛋白酶b抑制剂
CN101031548A (zh) N－(4－氟苄基)－n－(1－甲基哌啶－4－基)－n'－(4－(2－甲基丙氧基)－苯基甲基)脲的盐及其制备
CN1639159A (zh) N－氨基乙酰基－吡咯烷－2－腈和它们作为ddp－iv抑制剂的用途
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1173974C (zh) 作为p物质拮抗剂的哌啶基氨基甲基三氟甲基环醚化合物
CN1041830C (zh) 肽化合物
CN1759093A (zh) 用于制备1,2－二氨基化合物的不使用叠氮化物的方法
CN1137891C (zh) 生长激素促分泌素的制备方法
CN1062729A (zh) 可用作血管紧张肽转化酶抑制剂的含氨基和硝基的三环新化合物
CN1255498A (zh) 生长激素促分泌剂的制备方法和中间体
CN1025334C (zh) 新的谷氨酸衍生物的制备方法
CN1167710C (zh) 吡咯烷羰基氨基环状二硫化物
CN1194960C (zh) 4,5－二氨基莽草酸衍生物的制备方法
CN101076515A (zh) 制备3－吡咯烷－2－基－丙酸衍生物的新方法
CN1311785A (zh) 作为甘氨酸拮抗剂的四氢喹啉衍生物
CN1043504A (zh) 肽酶作用物的新型类似物
CN1168713C (zh) 制备鼻病毒蛋白酶抑制剂的合成路线以及关键的中间体
CN1243756C (zh) 用于制备头孢菌素的方法和酯衍生物
CN1135216A (zh) 光学活性咪唑烷酮衍生物及其制造方法
CN1950362A (zh) 类胰蛋白酶抑制剂的制备方法
CN1688307A (zh) 4－氨基哌啶衍生物,它们的制备方法和它们作为药物的用途
CN1041731C (zh) 吡啶并[1,2,3—d,e][1,3,4]苯并噁二嗪衍生物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: RAQUALIA PHAMA INC.

Free format text: FORMER OWNER: PFIZER PRODUCTS CO., LTD.

Effective date: 20100413

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: CONNECTICUT, AMERICA TO: AICHI-KEN,JAPAN

TR01 Transfer of patent right

Effective date of registration: 20100413

Address after: Aichi

Patentee after: Raqualia Pharma Inc.

Address before: American Connecticut

Patentee before: Pfizer Products Inc.

CX01 Expiry of patent term

Granted publication date: 20040211

CX01 Expiry of patent term